Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, March 11, 2019 at 4:00 PM to 4:30 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 07.11.16 in Vol 5, No 4 (2016): Oct-Dec

This paper is in the following e-collection/theme issue:

Works citing "A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS)"

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.6610):

(note that this is only a small subset of citations)

  1. Keller CW, Quast I, Dalakas MC, Lünemann JD. IVIG efficacy in CIDP patients is not associated with terminal complement inhibition. Journal of Neuroimmunology 2019;330:23
    CrossRef
  2. Kuwahara M, Kusunoki S. Mechanism and spectrum of anti-glycolipid antibody-mediated chronic inflammatory demyelinating polyneuropathy. Clinical and Experimental Neuroimmunology 2018;9(1):65
    CrossRef
  3. Uncini A, Vallat J. Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground. Journal of Neurology, Neurosurgery & Psychiatry 2018;89(6):627
    CrossRef
  4. Liu S, Dong C, Ubogu EE. Immunotherapy of Guillain-Barré syndrome. Human Vaccines & Immunotherapeutics 2018;:1
    CrossRef
  5. Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, Nagashima T, Shimizu T, Hirotani M, Kadoya M, Nakahara J, Shimizu J, Tanaka M, Sobue G, Katsuno M, Yamaguchi H, Ogata H. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. The Lancet Neurology 2018;17(6):519
    CrossRef
  6. Pilch KS, Spaeth PJ, Yuki N, Wakerley BR. Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases. Expert Review of Neurotherapeutics 2017;17(6):579
    CrossRef
  7. Yamagishi Y, Suzuki H, Sonoo M, Kuwabara S, Yokota T, Nomura K, Chiba A, Kaji R, Kanda T, Kaida K, Ikeda S, Mutoh T, Yamasaki R, Takashima H, Matsui M, Nishiyama K, Sobue G, Kusunoki S. Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study. Journal of the Peripheral Nervous System 2017;22(4):433
    CrossRef
  8. Wijdicks EF, Klein CJ. Guillain-Barré Syndrome. Mayo Clinic Proceedings 2017;92(3):467
    CrossRef